Value in Health

Article	Citations
Author Reply	719
Editorial Board	599
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	128
A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma	110
POSC161 Cost-Consequence Analysis of Rosuvastatin Versus Atorvastatin in the Spanish Setting	101
POSA371 Barriers and Expectations for Patients in Post-Osteoporotic Fractures Care in France: The Effel Study	97
POSA373 Evaluation of Ehealth Literacy Measurement Tools and Its Associated Factors: A Systematic Review and Meta-Analysis	77
POSB42 The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy	75
POSB62 Budget Impact Analysis of Ertugliflozin Inclusion in the List of Vital and Essential Medicines in Russian Federation	67
POSB55 Economic Consequences of Anti-HCV Treatment of Patients Diagnosed through Screening in Italy: A Prospective Modelling Analysis	67
A Systematic Review of International Guidance for Self-Report and Proxy Completion of Child-Specific Utility Instruments	64
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	63
Table of Contents	63
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	63
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	60
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	59
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	58
Editorial Board	58
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	54
HTA35 Testing and Piloting of a Value Framework for Diagnostic Technologies in Latin America	53
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	52
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	51
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	46
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	45
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	45

RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	42
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	42
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease	41
HTA70 Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer	40
RWD140 Using Machine Learning to Identify Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients from Electronic Health Record Data	40
RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis	39
EPH23 Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac	37
SA11 Data Visualization: A Tool to Enhance the Interpretability of Complex and Dense Data Sources	34
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	34
SA40 Indexing Regulatory Documents and Clinical Evidence Publications for Non-Small Cell Lung Cancer (NSCLC) Therapeutics: Establishing a Dataset to Enable the Study of Endpoint Fidelity	33
PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States	32
EPH158 Years of Life Lost Due to Diabetes Mellitus in Colombia, 1979-2017	32
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome	31
EPH61 Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD)	31
EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States	30
EPH69 Cancers Treatment from Their Perspective: A Qualitative Pilot Study Exploring the Knowledge Attitude and Practice of Folk Medicine Practitioners in a Low-and-Middle-Income-Country	30
PCR101 Item Response Theory Analysis of the Ilqi	30
EPH67 Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers” of Patients with Breast, Skin, GI, Female, Male, and "Other” Cancers	30
PCR102 Leveraging Social Media for Patient Experience Insights in Rare Disease	30
EE308 Real-World Treatment Patterns and Costs in Relapsed and Refractory Diffuse Large B-Cell Lymphoma in the United States	29
EE302 Households Out-of-Pocket Healthcare Expenditures Based on Number of Chronic Conditions in Riyadh, Saudi Arabia: A Quantile Regression Approach	29
CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population	29
EE139 Using a User-Friendly Modeling Tool to Inform and Guide Local Decision-Making for Lynch Syndrome Screening at Healthcare Systems	29
HPR59 Targeted and Immunotherapies for Cancer - Reimbursement and Expenditure in a Single-Payer Healthcare System in Bulgaria	28
EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US	28
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective	28
EE315 Economic Evaluation of Neutralising Monoclonal Antibodies for the Treatment of COVID-19 Positive People in the Community	28
PCR128 Rapid Review: Were There Any Clinical Trials in Non-Muscle Invasive Bladder Cancer That Naturally Adopted the Updated FDA COA Oncology Guidance?	28
PCR151 A Patient-Focused Approach to Understand Unmet Needs in Non-Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)	27
EE198 Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Essential Hypertension in Chinese Setting	27
HSD5 Changes in COVID-19 Treatment Patterns over the Course of 2020	27
PCR153 Navigating Barriers to Patient Participation in Qualitative Interviews from International Clinical Trials in Biliary Tract Cancer (BTC)	27
HTA72 Survival Extrapolation for Immuno-Oncology Drugs: Pessimism or Optimism? a Targeted Literature Review and a Validation-Based Case Study	26
EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada	26
HSD16 Trends in Rheumatology Patient Care and Practice Operations Pre- and Post-COVID-19 Pandemic	26
HSD79 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Tardive Dyskinesia	26
MSR30 Modelling Monthly Migraine Day Distribution: A Case Study of Fremanezumab Japanese-Korean Clinical Trials for Migraine Prevention	25
EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World	25
EE395 Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-35 Weeks' Gestation	25
MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis	24
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK	24
MSR45 Smooth Algorithm: An Automatic Method to Estimate the Most Likely Drug Combination in Electronic Health Records. Development and Validation Study	24
MSR23 A Machine Learning Approach to Score Employer Groups Based on How Well They Manage Their Specialty Drug Spend	24
EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience	24
EE406 Households Direct Economic Burden Associated with Chronic Non-Communicable Diseases in Saudi Arabia	24
P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L	23
POSB170 Economic Burden of Depression with Concurrent Anxiety in a General Population of US Adults Based on National Health and Wellness Survey (NHWS)	23
POSB187 Study of Awareness of Pharmacy Employees in Ukraine with the Problem of Antibiotics Resistance	23
POSC176 Is Pain Severity Associated with Functional Limitations Among United States Adults? A Cross-Sectional Study Using 2018 Medical Expenditure Panel Survey	23
POSB333 The Impact of Corrective Training on the Dynamic Axial Deviation of the Lower Limb Among Female Handball Players	23

POSB336 Comparative Study of Movement Patterns and Development During a 6-Week Training Programme for Triathletes and Orienteerers	22
POSB368 Understanding the Impact of Atopic Dermatitis in Portuguese Patients: Results from an Analytical Observational Study	22
P12 Are Gains in Health Utility Associated with Gains in Work Productivity and Role Functioning in Chronic Diseases? A Systematic Literature Review	22
POSC173 The Association Between Physical Activity, Body Mass Index and Health Complaints Among Hungarian School-Aged Children	22
POSC346 Quality of Life of Breast Cancer Patients Treated in a University Hospital in Alexandria, Egypt	22
POSB179 Epidemiological Disease Burden of Heart Failure, Unspecified Based on Routinely Collected Health Insurance Claims Data	22
POSC328 Impact of Treatment Schedule on Adherence and Persistence in Osteoporosis Patients Receiving Long-Acting Therapeutics	22
POSB213 Assessing the Changes of Hungarian Health Professional Workforce, Proportional to Population between 2003-2018	22
POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refract	21
POSB231 How to Determine Surgical Pathway Operating Costs in Chronic Rhinosinusitis with Nasal Polyposis Patients? The Time Driven Activity-Based Costing Experiment	21
Research Presentations Financial Disclosure Statements	21
POSB225 Differences and Similarities in the Methods: of Pricing of Prescription Drugs in Bulgaria, France, Germany, Belgium, and the UK: A Comparative Analysis	21
POSB240 The Effects of COVID-19 Infection on Medication Adherence with Chronic Therapies in Italy: The Fail-to-Refill Project	21
POSC17 A TARGETED LITERATURE REVIEW TO COMPARE COVID-19 SYMPTOM DIARIES AND PATIENT-REPORTED CONCEPT	21
POSC405 Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Musculoskeletal Conditions in the United States	20
POSB102 Systematic Literature Review on Cost-Effectiveness and Budget Impact Analysis of Robotic-Assisted Hysterectomy (RAH) for Benign and Malignant Gynecological Conditions	20
POSA64 The Life-Long Economic Burden of Immunoglobulin A Nephropathy (IGAN) in China	20
POSC238 Real World Data of Acute Pain Prescription in a Health District	19
POSA87 Annual Health Insurance Treatment Cost of Mental and Behavioural Disorders Due to Use of Opioids Based on Routinely Collected Financing Data	19
POSA89 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Peripheral Circulatory Complications Based on Routinely Collected Financing Data	19
POSC389 Characterisation of Existing Treatment Patterns in Muscle-Invasive Urothelial Carcinoma (MIUC) Across North America, Europe, and East Asia	19
POSA109 The Impact of Improving the Current Approach to Chronic Obstructive Pulmonary Disease Within the Spanish National Health System: A Social Return on Investment Analysis	19
POSB314 Method of Predicting Serotype Specific Effectiveness Against Invasive Pneumococcal Disease for Pneumococcal Conjugate Vaccines in Infant Population	19
POSC322 The Impact of Treatment Coefficient Parameterization for Mixture Cure Models on Cost-Effectiveness Models	19
POSA353 Conceptual Models of the Patient Experience of Duchenne Muscular Dystrophy Constructed from a Qualitative Interview Study with Caregivers	18
POSC138 The Burden Due to Moderate-to-Severe Paediatric Atopic Dermatitis Treated with Systemic Immunosuppressants on the Healthcare System in England	18
POSA368 Real-World Dietary Data Collection: Current Challenges and Opportunities for Innovation	18
P24 Telehealth Access and Use by the U.S. Medicare Population during the Pandemic	18
PCR76 Generating Health-State Utility Values in Patients Treated with Second-Line Systemic Therapy for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	17
HTA254 Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example	17
HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment	17
HTA350 Fixed Effect Versus Random Effects Bayesian Network Meta-Analyses in Practice: What Is Used to Inform National Institute for Health and Care Excellence (NICE) Technology Appraisals?	17
PCR49 A Preliminary Comparison between Analytical Hierarchy Process and Discrete Choice Experiment in Health State Preferences in Hong Kong SAR, China	17
PCR16 Uncovering the Influence of Smoking on Health Care Processes for Adult Lung Cancer Patients in Chile: Insights From a Multi-Perspective Qualitative Study	17
HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD	17
PCR62 Treatment Satisfaction and Health-Related Quality of Life in People Living With HIV Receiving DTG/3TC Who Are Treatment Experienced or Treatment Naive in Europe	17
HTA272 EUnetHTA's HTA Core Model®: A Critical Assessment and Future Outlook	17
PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients	17
PCR117 A Qualitative Interview Study into the Experiences of Fatigue and Depression in Chronic Hepatitis B	16
HPR192 Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?	16
PCR227 Do Family Spillover Effects of Illness Vary With the Age of the Ill Individual?	16
CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)	16
HPR66 Assessing the Impact and Strategic Implications of the HTA Regulation 2021/20282 on National Processes: A Scoping Review and Stakeholders Perspectives Through Semi-Structured Interviews	16
PCR122 Psychometric Evaluation of Multiple Sclerosis Impact Scale 29 Version 2 in Relapsing Multiple Sclerosis Patients Participating in a Phase 2 Study of Frexalimab	16
CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions	16
EE85 Health System Costs and Resources for Stage-Specific Breast Cancer: A Population-Based Approach (Updated)	16
RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study	16
CO71 Faricimab Versus Standard of Care in Naive Neovascular Age-Related Macular Degeneration Patients: An Indirect Treatment Comparison Using Individual Level Data	16
RWD100 Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review	16
HPR218 Recent Advances in Voluntary European Cross-Border Collaborations in Joint HTA and Drug Pricing/Procurement	16
HTA62 A Systematic Review of the New NICE Highly Specialised Technologies Criteria: How Do NICE Judge Criteria 3 and 4 to be Met?	16
EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome	16
EE31 Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis	15
EE321 Cost Impact of Next Generation Sequencing Testing in NSCLC with and without RNA Sequencing	15
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country	15
PCR87 Impact of Signs and Symptoms of Chronic Refractory Gout on Patient Health-Related Quality of Life	15
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future	15
EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia	15
EE554 Budget Impact Analysis of Intravenous Acetaminophen in Neonates after Esophageal Atresia and Tracheoesophageal Fistula Repair	15
EE359 Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian’s Health Syst	15
EE29 Cost-Effectiveness Analysis and Budgetary Impact of Telescopic Rods for Treatment of Fractures and Correction of Bone Deformities in Children with Osteogenesis Imperfecta in the Brazilian Public	15
PT41 Real-World Evidence in Rare Diseases in France: Treatment Patterns, Healthcare Resource Use, and Related Costs in Von Willebrand Disease (FORvWARD Study)	15
EE372 Descriptive Analysis of Botulinum Toxin Use for Migraine and Member Costs in an Employed Population	15
EE151 Cost-Minimization of Lorlatinib Versus Alectinib for First Line Treatment for Treatment of Alk-Positive Non–Small-Cell Lung Cancer from the Brazilian Private Healthcare System Perspective	15
Copyright/Subscription	15
EE549 Burden of Disease of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D) Using the Standard of Care in Peru	14
EE565 Health Economic Evaluations on Dengue Vaccine in Indonesia	14
MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain	14
EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis	14
HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis	14
EE156 Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia in Colombia	14
EE558 Key Methodological Considerations for Developing Cost-Offset Budget Impact Models for a Range of Medical Technologies and Cost Perspectives in Ophthalmology	14
RWD4 Socioeconomic Burden of Obesity – Increased Rate and Duration of Sick Leave in Patients Living with Obesity: A Cross-Sectional Claims Data Analysis in Germany	14
MSR82 Combating Sample Scarcity: A Novel Bayesian Approach to Pediatric Basket Trials	14
CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea	14
HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome	14
EE168 Budget Impact Analysis of Adopting Lanreotide in the Treatment of Acromegaly and GEP-NET at Public Hospitals in Saudi Arabia	14
SA56 Treatment Patterns of Advanced Egfr-Positive Non-Small Cell Lung Cancer (NSCLC) in Latin America	14
HSD113 Access to Medicines, Care, and Services for Multiple Sclerosis Patients in Central and Eastern European Countries: A Comparative Analysis	14
MSR84 Summarizing Adverse Event Data in the Absence of High-Level Evidence: The Case of Hearing Implants	14

EE555 Economic Burden of Cardiorespiratory Hospitalizations Associated With RSV Among US Adults, 2017-2019	13
EPH255 Healthcare Resource Consumption of Patients with Cardiovascular Events after Exacerbations of Chronic Obstructive Pulmonary Disease in Italy: Results from the EXACOS-CV Study	13
EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece	13
EE553 An Exploratory Study Assessing the Utility Impact in Second Informal Carers of Patients With Epidermolysis Bullosa	13
EE573 Economic Burden of Chronic Kidney Disease with Type 2 Diabetes in Turkiye	13
EE576 Costs Saving Generated by Anti-TNF Biosimilars Market Penetration in France: An Analysis Based on French Health Insurance Open Data	13
EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial	13
EE67 Insurer and Patient Costs for Repeat Breast Surgery After Initial Lumpectomy for Breast Cancer	13
HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK	13
HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?	12
HPR17 Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England	12
EE77 The Cost-Effectiveness of Tradition Chinese Medicine Icaritin Versus Cinobufotalin in Patients with Unresectable Advanced Hepatocellular Carcinoma in China	12
CO56 Radiographic Progression Free Survival as a Surrogate Endpoint for Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer	12
EE633 Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease	12
EE667 The Opportunity of High-Dose Vaccination Against Influenza for Adults Aged 60 and Above in the Netherlands	12
HPR25 Patient Organisations' Submissions to the Pharmaceutical Pricing Board in Finland	12
EPH184 The Relevance of Insomnia in Relation to Other High-Impact Pathologies. a Systematic Literature Review	12
EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions	12
EE402 Social and Economic Burden of Breast Cancer in Russia	12
EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy	12
EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population	12
EE458 Benefits, Costs and Cost Effectiveness of a Chronic Heart Failure Disease Management Program for Austria – a Decision-Analytic Modeling Study	12
EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada	11
RWD99 The Financial Burden of DM on the Public Health System of Greece: Using Big Data From Greece	11
HTA196 Influence of REvalMED Pilot Program on Drug Evaluations in Spain: An Analysis of Therapeutic Positioning Reports	11
RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US	11
MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods	11
EE429 Cost-Effectiveness and Budget Impact Analyses of Enzalutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Mexico	11
HTA184 Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations	11
EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China	11
CO83 Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Surgery After the Implementation of Patient Blood Management (PBM) in Spain	11
HTA154 Comparing Non-Oncological Rare Condition Submissions to the National Institute for Health and Care Excellence (NICE) Versus Scottish Medicines Consortium (SMC) From 2001 to 2021	11
EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting	11
PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer	11
EE508 Work Productivity Loss Among Women With Menopausal Symptoms: A Systematic Literature Review	11
HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany	11
HSD31 Analysis of the Balanced Scorecard's Managerial Subdimensions in Health Care Organizations During the COVID-19 Pandemic	10
EE172 The Wisdom Self-Management Intervention: A Cost-Effectiveness Analysis to Support the Transformation of Type 2 Diabetes Care in England	10
EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan	10
HPR50 Challenges That EUnetHTA21 Will Have to Address to Make a Success of Joint Clinical Assessments	10
EPH177 Assessing Student Pharmacists’ Knowledge and Perceptions of Electronic Nicotine Delivery Systems (ENDS) – A Cross Sectional Study at One College of Pharmacy	10
EPH198 Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial)	10
SA60 Seeking ISPOR Abstracts: Is Searching Embase Enough?	10
CO52 Impact of Digital Interventions on Maintenance Treatment Adherence in Asthma: A Systematic Literature Review (SLR) and Meta-Analysis	10
EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan	10
RWD141 Exploration of Melanoma Patient-Generated Real-World Data Using an Ai-Based Social Listening Approach	10
MT28 A Systematic Literature Review of the Burden Associated with Insertion of Non-Tunneled Central Venous Catheters and the Effectiveness of Ultrasound-Guided Insertion	10
HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Commi	10
EE190 Association of Total Annual Costs of Duchenne Muscular Dystrophy With Disease Severity	10
MSR110 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Hazard Ratio-Based Network Meta-Analysis	10
HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review	10
EPH142 The Burden of Metastatic or Inoperable HER2+ Breast Cancer on the Italian Health System	10
EE506 Budget Impact Analysis of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico	10
PCR75 Comparing Choice Share Prediction Methods for Discrete Choice Experiments: A Case Study With Hypomethylating Agents in Myelodysplastic Syndromes	10
PCR11 Understanding the Patient Experience of Erythropoietic Protoporphyria and X-Linked Protoporphyria: A Qualitative Study	10
CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy	9
EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finlan	9
CO109 Patient-Reported Improvements in “Off”-Time Quality, Non-Motor Fluctuation Severity, and Medication Satisfaction in the Real-World Opti-on Study of Opicapone in Parkinson’s Disease	9
Cover	9
PCR216 Insights from Social Media Posts on the Lived Experience of Alzheimer's Disease	9
EE442 Direct Expenses Study of Liver Transplantation Treatment	9
EPH90 Incidence Rate of Infections and Association between Lupus Nephritis and Serious Infections in Patients with Systemic Lupus Erythematosus: Systematic Literature Review and Meta-Analyses	9
EE375 Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients With HR+/HER2- Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours	9
HPR24 Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured and after Transition to Medicare Advantage Versus Traditional Fe	9
PCR195 Developing a Framework to Capture Economic Impacts on Patients and Caregivers: Recommendations to Guide Patient-Centered Outcomes Research and Value Assessment	9
HPR43 The Influence and Implementation of Pathways of Care for Hematologists Compared to Oncologists in the United States	9
RWD38 Quality of Electronic Health Records: Managing Aggregated Patient Demographic Information	9
PCR222 The Value of No Cancer Signal Detected Results from Multi-Cancer Early Detection Tests–Perspectives of People in the General Population	9
EE23 Economic Impact of Discontinuation and Relapse Rates Among Patients with Schizophrenia Newly Initiated on Lybalvi Versus Olanzapine during First Year Use	9
CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-A	9
HSD53 Analysis of the Balanced Scorecard's Internal Subdimensions in Health Care Organizations During the COVID-19 Pandemic	9
HSD43 COPD Patients Receiving Fixed or Open-Label Triple Therapy: Initiation and Persistence of Treatment Based on Data From a Real-World Ambulatory Medicalized Database in France	9
PCR169 A Systematic Literature Review (SLR) of Health State Utility Values (HSUV) in Metastatic Castration-Resistant Prostate Cancer (MCRPC)	9
HPR45 Analysis of Alternative Access Routes and Time to Access for Paediatric Indication Expansions with Consideration of Regulatory, Pricing, and Access Incentives	9
PCR205 Assessment of Healthcare Resource Utilization in Patients with Exocrine Pancreatic Insufficiency in the Pact-CP Registry	9
RWD53 Assessing the Association of Various Characteristics with Perceived Health Status Among Adults with Skin Cancer in the United States	9
HTA51 Impact of ICER Assessments on Payer Decision Making in the United States	9
EE214 Modelling Cost Determinants for Treating Metastatic Castration-Resistant Prostate Cancer: An Italian National Healthcare System's Perspective Cost Analysis	9
HPR102 Exploring the Cost of Managing Diabetes in Nepal: A Cross-Sectional Analysis of Oral Hypoglycemic Medications	8
HTA33 Does the Selection of Participating Regions Impact the Outcome of Spanish Therapeutic Positioning Reports?	8
EE133 Budget Impact Related to Complications on Post-Bariatric Surgery Patients in Brazilian Public Healthcare System	8
OP14 Racial and Ethnic Minority Inclusion in Clinical Outcome Assessment (COA) Research: A Reflection on Current Practices	8
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study	8
HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment	8
MSR47 Feasibility Assessment of Indirect Treatment Comparison of Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps	8
EE128 Facing the Challenge of Ageing: Cost-Effectiveness of the SPRINT-T Protocol	8
EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France	8
EPH118 Healthcare Systems Sustainability and Resilience: Creating an Index	8
EPH82 Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study	8
EE438 Assessing the Budget Impact of Automated Diabetic Retinopathy Screening: A Budget Impact Analysis in Germany	8
RWD55 Predicting Metastatic Disease Progression in Prostate Cancer Patients Using Machine Learning of PSA Kinetics	8
HSD35 If Primary Prevention Is the Solution, Why Don't We Take Advantage of All Opportunities in Brazil?	8
CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting	8
EPH96 Risk Factors for Below-the-Knee Amputation in Japanese Patients With Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis	8
HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany	8